{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:46:56Z","timestamp":1791686816137,"version":"4.3.4"},"reference-count":80,"publisher":"SAABRON PRESS","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Treatment options for newly diagnosed multiple myeloma (NDMM) have expanded dramatically over the last two decades, resulting in remarkable improvements in response rates and median survival times. In eligible patients, autologous stem cell transplant plays the central role of an overall treatment strategy comprising induction, transplantation, consolidation, and maintenance. In this article, we draw from our own collective clinical experience of treating patients with NDMM in the Gulf region to discuss treatment strategies in both transplant-eligible and -ineligible patients, as well as in high-risk patients. We present position statements for these distinct patient populations specifically for treatment in the Gulf region, where patients with NDMM have a younger median age than and different comorbidity profile from Western populations. We discuss how the introduction of anti-CD38 agents, including daratumumab and isatuximab, have had a major impact on the frontline treatment landscape in MM, with daratumumab-based quadruplet and triplet regimens emerging as the new standard of care in transplant-eligible and -ineligible patients, respectively. In addition, we advocate aggressive quadruplet treatment of high-risk patients with NDMM, as part of a strategy including single or tandem transplant when eligible. Finally, we discuss the clinical and practical rationale behind our statements, which is intended to serve as a useful reference for hematologists treating physicians within the Gulf region and beyond.<\/jats:p>","DOI":"10.46989\/001c.128113","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:47:37Z","timestamp":1739252857000},"source":"Crossref","is-referenced-by-count":3,"title":["Frontline management of multiple myeloma patients: optimizing treatment for patients in the Gulf region"],"prefix":"10.46989","volume":"7","author":[{"given":"Mahmoud","family":"Marashi","sequence":"first","affiliation":[{"name":"Department of Hematology, Mediclinic City Hospital and Dubai Hospital, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Al Farsi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/049xx5c95","id-type":"ROR","asserted-by":"publisher"}],"name":"Sultan Qaboos University Hospital","department":["Department of Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussni","family":"Al Hateeti","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00gk5fa11","id-type":"ROR","asserted-by":"publisher"}],"name":"Sheikh Shakhbout Medical City","department":["Department of Medicine, Division of Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alhuraiji","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0249jjk91","id-type":"ROR","asserted-by":"publisher"}],"name":"Kuwait Cancer Control Center","department":["Department of Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Elsabah","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02d4f9f51","id-type":"ROR","asserted-by":"publisher"}],"name":"National Center for Cancer Care and Research","department":["Department of Hematology and Bone Marrow Transplantation"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honar","family":"Cherif","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02d4f9f51","id-type":"ROR","asserted-by":"publisher"}],"name":"National Center for Cancer Care and Research","department":["Department of Hematology and Bone Marrow Transplantation"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Hamad","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02d4f9f51","id-type":"ROR","asserted-by":"publisher"}],"name":"National Center for Cancer Care and Research","department":["Pharmacy Department"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayane","family":"Mheidly","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00gk5fa11","id-type":"ROR","asserted-by":"publisher"}],"name":"Sheikh Shakhbout Medical City","department":["Department of Medicine, Division of Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Osman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/007a5h107","id-type":"ROR","asserted-by":"publisher"}],"name":"Tawam Hospital","department":["Department of Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02en5vm52","id-type":"ROR","asserted-by":"publisher"}],"name":"Sorbonne Universit\u00e9","department":["Department of Clinical Hematology and Cellular Therapy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"Supplement_1","key":"ref1","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1182\/blood-2019-128769","article-title":"First Review of Multiple Myeloma Patients in Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates","volume":"134","author":"M. Abu Haleeqa","year":"2019","journal-title":"Blood"},{"issue":"2","key":"ref2","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1002\/mco2.146","article-title":"Pathogenesis and Treatment of Multiple Myeloma","volume":"3","author":"P. Yang","year":"2022","journal-title":"MedComm"},{"issue":"10","key":"ref3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/17474086.2023.2246651","article-title":"Role of Daratumumab in the Frontline Management of Multiple Myeloma: A Narrative Review","volume":"16","author":"S. Yadav","year":"2023","journal-title":"Exp Rev Hematol"},{"key":"ref4","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Multiple Myeloma Version 4.2024","year":"2024"},{"issue":"14","key":"ref5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"M. Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"ref6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"P. G. Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"9758","key":"ref7","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Dexamethasone as Induction Therapy before, and Consolidation Therapy after, Double Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Randomised Phase 3 Study","volume":"376","author":"M. Cavo","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"ref8","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of Bortezomib, Thalidomide, and Dexamethasone (VTD) as Induction Pretransplantation Therapy in Multiple Myeloma: A Randomized Phase 3 PETHEMA\/GEM Study","volume":"120","author":"L. Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"issue":"22","key":"ref9","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus Dexamethasone versus Reduced-Dose Bortezomib, Thalidomide plus Dexamethasone as Induction Treatment before Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma","volume":"118","author":"P. Moreau","year":"2011","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1197340","DOI":"10.3389\/fonc.2023.1197340","article-title":"Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma","volume":"13","author":"L. Rosi\u00f1ol","year":"2023","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1178224219868235","DOI":"10.1177\/1178224219868235","article-title":"Multiple Myeloma: An Overview of Management","volume":"13","author":"S. A. Bird","year":"2019","journal-title":"Palliat Care Soc Pract"},{"issue":"8","key":"ref12","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial","volume":"136","author":"P. M. Voorhees","year":"2020","journal-title":"Blood"},{"issue":"4","key":"ref13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"P. Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"ref14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/ijms22020888","article-title":"Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy","volume":"22","author":"S. Yamamoto","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10192","key":"ref15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"P. Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"S1470204524002821","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab and Followed by Daratumumab Maintenance or Observation in Transplant-Eligible Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the CASSIOPEIA Randomised Controlled Phase 3 Trial","author":"P. Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"ref17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients","volume":"142","author":"F. Gay","year":"2023","journal-title":"Blood"},{"issue":"3","key":"ref18","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-Analysis","volume":"4","author":"A. J. Waxman","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"ref19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.12965\/jer.1938758.379","article-title":"Prevalence of Metabolic Syndrome in the Gulf Cooperation Council Countries: Meta-Analysis of Cross-Sectional Studies","volume":"16","author":"S. Shin","year":"2020","journal-title":"J Exerc Rehabil"},{"issue":"3","key":"ref20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4103\/HMJ.HMJ_37_18","article-title":"Prevalence and Risk Factors of Cardiovascular Disease in the United Arab Emirates","volume":"11","author":"H. Razzak","year":"2018","journal-title":"Hamdan Med J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1338552","DOI":"10.3389\/fmed.2024.1338552","article-title":"Real World Evidence of Epidemiological Trends, Clinical Presentation, and Prognostic Outcomes of Multiple Myeloma (2007-2021)","volume":"11","author":"H. Elsabah","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"ref22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/cells13100853","article-title":"Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy","volume":"13","author":"S. Rocchi","year":"2024","journal-title":"Cells"},{"issue":"6","key":"ref23","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.3390\/cancers13061322","article-title":"Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM","volume":"13","author":"F. Bachmann","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref24","article-title":"REVLIMID (Lenalidomide) Prescribing Information","year":"2023"},{"issue":"Supplement 1","key":"ref25","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1182\/blood-2022-165376","article-title":"Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial","volume":"140","author":"C. Pawlyn","year":"2022","journal-title":"Blood"},{"issue":"18","key":"ref26","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and Dexamethasone Maintenance with or without Ixazomib, Tailored by Residual Disease Status in Myeloma","volume":"142","author":"L. Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"issue":"10","key":"ref27","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","article-title":"Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-Analysis","volume":"4","author":"F. Gay","year":"2018","journal-title":"JAMA Oncol"},{"issue":"Supplement 1","key":"ref28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2023-177564","article-title":"Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study","volume":"142","author":"N. W. C. J. Van De Donk","year":"2023","journal-title":"Blood"},{"key":"ref29","article-title":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma"},{"issue":"1","key":"ref30","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline Treatment Patterns and Attrition Rates by Subsequent Lines of Therapy in Patients with Newly Diagnosed Multiple Myeloma","volume":"20","author":"R. Fonseca","year":"2020","journal-title":"BMC Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"100476","DOI":"10.1016\/j.ctarc.2021.100476","article-title":"Supportive Care in Multiple Myeloma: Current Practices and Advances","volume":"29","author":"T. S. Miceli","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"10068","key":"ref32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone Alone in Patients with Newly Diagnosed Myeloma without Intent for Immediate Autologous Stem-Cell Transplant (SWOG S0777): A Randomised, Open-Label, Phase 3 Trial","volume":"389","author":"B. G. M. Durie","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"ref33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"M. A. Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"ref34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer Term Follow-up of the Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)","volume":"10","author":"B. G. M. Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"ref35","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A Phase 2 Study of Modified Lenalidomide, Bortezomib and Dexamethasone in Transplant-Ineligible Multiple Myeloma","volume":"182","author":"E. K. O\u2019Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"ref36","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1182\/blood-2019-128000","article-title":"Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-Lite) in Transplant-Ineligible Multiple Myeloma","volume":"134","author":"E. K. O\u2019Donnell","year":"2019","journal-title":"Blood"},{"issue":"22","key":"ref37","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"T. Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"ref38","doi-asserted-by":"publisher","first-page":"10150","DOI":"10.1182\/blood-2022-163335","article-title":"Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study","volume":"140","author":"S. K. Kumar","year":"2022","journal-title":"Blood"},{"issue":"12","key":"ref39","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.25963","article-title":"Daratumumab-lenalidomide-dexamethasone vs Standard-of-care Regimens: Efficacy in Transplant-ineligible Untreated Myeloma","volume":"95","author":"B. G. M. Durie","year":"2020","journal-title":"Am J Hematol"},{"issue":"15_suppl","key":"ref40","doi-asserted-by":"publisher","first-page":"TPS8056","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8056","article-title":"Bortezomib, Lenalidomide, and Dexamethasone (VRd) \u00b1 Daratumumab (DARA) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) for Whom Transplant Is Not Planned as Initial Therapy: A Multicenter, Randomized, Phase III Study (CEPHEUS)","volume":"37","author":"S. Zweegman","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref41","article-title":"A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant Is Not Planned as Initial Therapy"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02344-9","article-title":"Daratumumab SC + Bortezomib\/Lenalidomide\/Dexamethasone in Patients With Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study","author":"S. Z. Usmani","journal-title":"21st International Myeloma Society (IMS) Annual Meeting, Rio de Janeiro, Brazil, 2024"},{"issue":"6","key":"ref43","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"M.-V. Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"ref44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple Myeloma: Available Therapies and Causes of Drug Resistance","volume":"12","author":"V. Pinto","year":"2020","journal-title":"Cancers"},{"issue":"10218","key":"ref45","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall Survival with Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma (ALCYONE): A Randomised, Open-Label, Phase 3 Trial","volume":"395","author":"M.-V. Mateos","year":"2020","journal-title":"Lancet"},{"issue":"Supplement 1","key":"ref46","doi-asserted-by":"publisher","first-page":"10157","DOI":"10.1182\/blood-2022-163347","article-title":"Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study","volume":"140","author":"M.-V. Mateos","year":"2022","journal-title":"Blood"},{"issue":"14","key":"ref47","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1182\/bloodadvances.2023012539","article-title":"Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Transplant-Ineligible Myeloma: AMaRC 03-16","volume":"8","author":"P. Mollee","year":"2024","journal-title":"Blood Advances"},{"issue":"9","key":"ref48","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/jcm10091841","article-title":"Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies-Current Research and Clinical Approaches","volume":"10","author":"A. Poczta","year":"2021","journal-title":"J Clin Med"},{"issue":"16_suppl","key":"ref49","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1200\/JCO.2024.42.16_suppl.7500","article-title":"Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) versus VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (IMROZ)","volume":"42","author":"T. Facon","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref50","article-title":"SARCLISA (Isatuximab) Prescribing Information","year":"2024"},{"issue":"S2","key":"ref51","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.HS9.0000936192.21618.f2","article-title":"P16 Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial","volume":"7","author":"T. Facon","year":"2023","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"ref52","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1182\/blood-2022-159933","article-title":"A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial","volume":"140","author":"S. Manier","year":"2022","journal-title":"Blood"},{"key":"ref53","article-title":"Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy (IFM2017_03)"},{"issue":"7","key":"ref54","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41375-019-0384-1","article-title":"Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Including Ixazomib Maintenance","volume":"33","author":"S. K. Kumar","year":"2019","journal-title":"Leukemia"},{"key":"ref55","article-title":"Multiple Myeloma","year":"2022"},{"issue":"25","key":"ref56","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study","volume":"39","author":"C. A. M. Stege","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/hematology.2021000229","article-title":"High-Risk Multiple Myeloma: How to Treat at Diagnosis and Relapse?","volume":"2021","author":"M.-V. Mateos","year":"2021","journal-title":"Hematology"},{"issue":"2","key":"ref58","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The Relative Importance of Factors Predicting Outcome for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial","volume":"34","author":"C. Pawlyn","year":"2020","journal-title":"Leukemia"},{"issue":"41","key":"ref59","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1200\/EDBK_320105","article-title":"How to Treat High-Risk Myeloma at Diagnosis and Relapse","author":"J. Caro","year":"2021","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"11","key":"ref60","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-Risk Cytogenetic Factors: A Systematic Review and Meta-Analysis","volume":"6","author":"S. Giri","year":"2020","journal-title":"JAMA Oncol"},{"issue":"7","key":"ref61","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1093\/oncolo\/oyac067","article-title":"Daratumumab Improves Depth of Response and Progression-Free Survival in Transplant-Ineligible, High-Risk, Newly Diagnosed Multiple Myeloma","volume":"27","author":"A. J. Jakubowiak","year":"2022","journal-title":"The Oncologist"},{"issue":"1","key":"ref62","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41408-024-01088-6","article-title":"Daratumumab in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of Clinically Relevant Subgroups in GRIFFIN","volume":"14","author":"A. Chari","year":"2024","journal-title":"Blood Cancer J"},{"issue":"12","key":"ref63","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/17474086.2021.1983427","article-title":"Chromosomal 1q21 Abnormalities in Multiple Myeloma: A Review of Translational, Clinical Research, and Therapeutic Strategies","volume":"14","author":"K. Bisht","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"25","key":"ref64","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","volume":"40","author":"L. J. Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref65","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma (MASTER): Final Report of the Multicentre, Single-Arm, Phase 2 Trial","volume":"10","author":"L. J. Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"ref66","doi-asserted-by":"publisher","DOI":"10.46989\/001c.92555","article-title":"Epidemiology, Treatment Trends, and Outcomes of Multiple Myeloma in the Middle East and Africa: A Systematic Review","volume":"6","author":"M. Mattar","year":"2024","journal-title":"Clinical Hematology International"},{"issue":"23","key":"ref67","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma","volume":"41","author":"M. F. Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26530","article-title":"Tandem Autologous Stem Cell Transplantation in Patients with Persistent Bone Marrow Minimal Residual Disease after First Transplantation in Multiple Myeloma","volume":"97","author":"M. Mohan","year":"2022","journal-title":"American J Hematol"},{"issue":"6","key":"ref69","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous Haematopoietic Stem-Cell Transplantation versus Bortezomib-Melphalan-Prednisone, with or without Bortezomib-Lenalidomide-Dexamethasone Consolidation Therapy, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (EMN02\/HO95): A Multicentre, Randomised, Open-Label, Phase 3 Study","volume":"7","author":"M. Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"ref70","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1182\/blood-2023-174044","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04","volume":"142","author":"C. Touzeau","year":"2023","journal-title":"Blood"},{"issue":"1","key":"ref71","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma","volume":"42","author":"L. B. Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref72","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after High-Dose Therapy in Myeloma: Long-Term Results from the Phase III HOVON-65\/GMMG-HD4 Trial","volume":"32","author":"H. Goldschmidt","year":"2018","journal-title":"Leukemia"},{"issue":"14","key":"ref73","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/cncr.34778","article-title":"Impact of Bortezomib-based versus Lenalidomide Maintenance Therapy on Outcomes of Patients with High-risk Multiple Myeloma","volume":"129","author":"N. Bumma","year":"2023","journal-title":"Cancer"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"638653","DOI":"10.3389\/fendo.2021.638653","article-title":"Editorial: Diabetes in the Middle East","volume":"12","author":"M. Abu-Farha","year":"2021","journal-title":"Front Endocrinol"},{"issue":"11","key":"ref75","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.3390\/ijms25116192","article-title":"Current Novel Targeted Therapeutic Strategies in Multiple Myeloma","volume":"25","author":"C. H.-T. Lin","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"5","key":"ref76","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T Therapies in Multiple Myeloma: Unleashing the Future","volume":"31","author":"M. Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"ref77","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the Global, Regional, and National Burden of Multiple Myeloma from 1990 to 2019","volume":"21","author":"L. Zhou","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"ref78","doi-asserted-by":"publisher","first-page":"e432204","DOI":"10.1200\/EDBK_432204","article-title":"Charting the Course: Sequencing Immunotherapy for Multiple Myeloma","volume":"44","author":"M. Mohan","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"ref79","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.3390\/curroncol30060396","article-title":"Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes","volume":"30","author":"M. Tanguay","year":"2023","journal-title":"Curr Oncol"},{"key":"ref80","article-title":"Longevity and Ageing Populations in the GCC"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/128113-frontline-management-of-multiple-myeloma-patients-optimizing-treatment-for-patients-in-the-gulf-region","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:06:42Z","timestamp":1791684402000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/128113-frontline-management-of-multiple-myeloma-patients-optimizing-treatment-for-patients-in-the-gulf-region"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.128113","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}